Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

ConclusionsSerial cardiac monitoring can be safely omitted in non-smoking patients with baseline LVEF  >  60% and without cardiotoxicity during prior neoadjuvant/adjuvant treatment.

Source: Breast Cancer Research and Treatment - January 4, 2021 Category: Cancer & Oncology Source Type: research